Latest Administration News

Solution Dynamics Limited reported an 85% drop in net profit for FY2026 to NZD 0.38 million, hit by a major contract loss and investment in its new AI-driven dental marketing platform, nGAGE.

New Zealand Rural Land Company posted a 36% rise in net profit for the first half of 2026 but suspended full-year guidance due to the liquidation of a key tenant, Kiwi Crunch Farms, which represents nearly 6% of rental income.

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.

ParagonCare’s FY26 results show modest revenue and underlying earnings growth, overshadowed by a large credit loss provision related to the Infinity Pharmacy Group debt.

Urbanise.com Limited reported 14.3% revenue growth to $15 million in FY2026, significantly narrowing its net loss to $0.9 million while advancing a NAB partnership pilot and launching AI features.

FAR Limited swung to a US$1.44 million profit for H1 2026, driven by contingent payments from its Senegal asset sale, and completed a substantial A$32.3 million capital return to shareholders.

Netwealth Group posted record FY26 revenue of $391 million, up 21%, with adjusted net profit rising 16.2% to $135.4 million after excluding $105 million in First Guardian compensation. The company declared a fully franked 21-cent final dividend, maintaining a 9.1% increase in total dividends.

HiTech Group has secured unconditional ACCC clearance for its acquisition of Hudson Global Resources’ Australian assets, removing a major regulatory obstacle ahead of completion.

Monvia Limited reported a $28.7 million revenue year with a $6.9 million adjusted EBITDA, exceeding IPO forecasts, while renewing a $60 million contract with MetLife and completing its ASX listing.

Winton Land reported a 120% rise in net profit to $22.7 million in FY26, driven by increased residential settlements and full-year trading at its hospitality venues, despite economic headwinds and leadership changes.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Centrepoint Alliance reported a 24% jump in net profit to $6.4 million for FY26, underpinned by a 16% rise in EBITDA and advances in artificial intelligence initiatives. The company declared a steady fully franked dividend of 1.75 cents per share and expanded its salaried advice business through acquisitions.